Using kallikrein-related peptidases (KLK) as novel cancer biomarkers

References
1 Frey EK. Zusammenhänge zwischen Herzarbeit und Nierentätigkeit. Arch Klin Chir 1926; 142: 663-669.
2 Frey EK, Kraut H. Über einen von der Niere ausgeschiedenen, die Herztätigkeit anregenden Stoff. Hoppe-Seyler’s Z Physiol Chem 1926; 157: 32-61.
3 Kraut H. et al. Über die Inaktivierung des Kallikreins. Hoppe-Seyler’ s Z Physiol Chem 1930; 192: 1-21.
4 Werle E. et al. Über die Wirkung des Kallikreins auf den isolierten Darm und über eine neue darmkontrahierende Substanz. Biochem Z 1937; 289: 217-233.
5 Sainz IM. et al. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 2007; 98: 77-83.
6 Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-890.
7 Lundwall A, Brattsand M. Kallikrein-related peptidases. Cell Mol Life Sci 2008; 65: 2019-2038.
8 Schedlich LJ. et al. Primary structure of a human glandular kallikrein gene. DNA 1987; 6: 429-437.
9 Rao AR. et al. The discovery of prostate-specific antigen. Br J Urol Int 2008; 101: 5-10.
10 Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987; 214: 317-322.
11 Gan L. et al. Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene 2000; 257: 119-130.
12 Harvey TJ. et al. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000; 275: 37397-37406.
13 Yousef GM. et al. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 2000; 276: 125-133.
14 Lundwall A. et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006; 387: 637-641.
15 Clements JA. et al. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004; 41: 265-312.
16 Klokk TI. et al. Human Tissue Kallikreins – A Family with many surprises. Turk J Biochem 2006; 31: 69-78.
17 Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53: 1423-1432.
18 Paliouras M. et al. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007; 249: 61-79.
19 Harbeck N. et al. Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Crit Rev Clin Lab Sci 2007; 44: 179-201.
20 Folgueras AR. et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 2004; 48: 411-424.
21 Ramirez ML. et al. Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Dis 2008; 11: 216-229.
22 Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem 2008; 54: 1600-1607.
23 Dorn J. et al. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. Clin Cancer Res 2007; 13: 1742-1748.
24 Talieri M. et al. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost 2004; 91: 180-186.
25 Yousef GM. et al. Differential expression of Kallik-rein gene 5 in cancerous and normal testicular tissues. Urology 2002; 60: 714-718.
26 Prezas P. et al. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biol Chem 2006; 387: 1607-1612.
27 Stavropoulou P. et al. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta 2005; 357: 190-195.
28 Thomadaki H. et al. Treatment of PC3 prostate cancer cells with mitoxanthrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb Haemost 2009; 101: 373-380.
29 Papachristopoulou G. et al. Expression analysis and study of KLK4 in benign and malignant breast tumors. Thromb Haemost 2009; 101: 381-387.
30 Kontourakis P. et al. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thromb Haemost. 2009 101: epub ahead of print Jan 15, 2009.
31 Talieri M. et al. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb Haemost. 2009 in print.
32 Borgoño CA. et al. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin Cancer Res 2006; 12: 1487-1493.
33 Bhoola KD. et al. Current status of tissue kallikrein inhibitors: importance in cancer. Curr Opin Investig Drugs 2007; 8: 462-468.
34 Debela M. et al. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem 2008; 389: 623-632.